Editas Medicine Inc Stock Price. Everything You Need To Know About The Editas Medicine Inc Stock! Editas Medicine Inc Stock Price. Everything You Need To Know About The Editas Medicine Inc Stock!


Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 226 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cas12a), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The company is engaged in the development of in vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, EDIT-301, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta-thalassemia (TDT).



Editas Medicine Inc Stock Price. Everything You Need To Know About The Editas Medicine Inc Stock! performance

  • Employees 226
  • Company HQ Cambridge
  • Website https://www.editasmedicine.com/
  • EDIT Asset Type Common Stock
  • EDIT Market Capitalization 427.6M
  • Earnings Per Share -2.07
  • Dividends Per Share None
  • Dividend Date None
  • Quarterly Earnings Growth 0

Editas Medicine is a promising biotechnology company that focuses on developing novel genome editing therapies to treat various genetic diseases. Are you a retail investor from Malaysia, Thailand, Indonesia, or Vietnam interested in investing in this innovative stock? Look no further. Zorion, the leading investment platform, provides you with the opportunity to invest in Editas Medicine and make informed decisions. Our platform offers comprehensive investment insights and recommendations specific to your region. With access to resources and educational materials, you can further expand your investment knowledge and enhance your investment strategies. Don’t miss out on the chance to invest in Editas Medicine and be a part of the genome-editing revolution. Start your investing journey with Zorion today!


Want To Buy Editas Medicine Inc Stock From Malaysia, Indonesia, Thailand or Philippines? You may also be interested in: